Navigation Links
Roswell Park Presentations at TCT Meeting Focus on Tools for Predicting Patient Outcomes
Date:2/22/2019

Particularly in the realm of cancer care, which can mean years of treatment and follow-up for patients, clinicians look to a number of tools and metrics to guide their decision-making regarding what, if any, treatment options and care approaches may be most effective for a particular patient. Roswell Park Comprehensive Cancer Center experts were invited to highlight ways to optimize these predictive strategies to improve both treatment and rehabilitation of patients undergoing hematopoietic stem cell transplantation, also known as bone marrow transplant, during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.

Theresa Hahn, PhD, earned a Best Abstract Award from the meeting organizers for her work to better predict the long-term risk of disease progression or death in multiple myeloma patients treated with hematopoietic cell transplant followed by long-term, “maintenance” doses of the immunomodulating drug lenalidomide. Dr. Hahn led a multicenter team of collaborators from Roswell Park, the Center for International Blood and Marrow Transplant Research, the Medical College of Wisconsin and the Blood and the Marrow Transplant Clinical Trials Network in this effort to determine whether a patient’s status as either positive or negative for minimal residual disease, or MRD, in the bone marrow at key junctures during the course of treatment could accurately predict how long their disease would remain well-controlled.

There are several unique aspects of the team’s approach to determining prognosis for patients with multiple myeloma. Their study, called Prognostic Immunophenotyping for Myeloma Response (PRIMeR), was the first major effort in the U.S. to look at this metric of MRD as an indicator of prognosis for newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant as part of primary therapy. It’s also the first U.S. study to measure MRD in patients with multiple myeloma at three key junctures, using next-generation flow cytometry: before transplant (baseline), after transplant but before maintenance therapy is initiated (pre-maintenance) and one year following hematopoietic cell transplant (at one year).

The team found that MRD status is prognostic for progression-free survival (PFS) at all measured timepoints, and for overall survival at one year, performing better than other existing predictive tools for newly diagnosed multiple myeloma patients. But their findings also point to an opportunity to improve treatment for some patients who have minimal residual disease upon bone marrow testing. Also, while maintenance therapy with lenalidomide has significantly improved survival for patients with multiple myeloma, about 1 in 5 patients who showed no evidence of residual disease at one year still went on to experience disease progression.
“Multiple myeloma remains an incurable disease, but we have more and better treatment options than ever before,” notes Dr. Hahn, a Professor of Oncology with the Department of Medicine at Roswell Park. “What’s most exciting about this approach is that it may help us figure out sooner which patients may benefit from a change in their treatment regimen.”

The study, “Minimal Residual Disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for Multiple Myeloma: Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study,” is TCT 2019 abstract no. 6. Dr. Hahn’s talk is scheduled for Friday, Feb. 22 from 4:35 to 4:50 p.m. CST during the Best Abstracts Session, to be held in the George R. Brown Convention Center, GRB-Grand Ballroom ABC.

Other highlights of Roswell Park’s participation in TCT 2019:

  • Jordan Pleskow, PharmD, from Roswell Park’s Clinical Pharmacy Service will give a talk entitled “BMT 101: Reimmunization in Post-Hematopoietic Stem Cell Transplant Patients,” discussing considerations around the vaccinations that are given to patients following transplant in order to prevent infectious diseases from developing.

“I will highlight the importance of vaccination for patients undergoing transplant and cell therapy, but also the need to hold off on giving some of these vaccinations in some cases,” notes Dr. Pleskow. “Vaccinations are especially important for patients who are receiving immunosuppressive therapy, but the type and timing of administration can vary considerably from therapy to therapy and patient to patient. We’re just beginning to understand the role of vaccines for patients receiving immune effector therapy treatments such as chimeric antigen receptor T cell or CAR-T therapy, so there’s a lot of new information to discuss.”

Dr. Pleskow will give his presentation today, Thursday, Feb. 21, from 4 to 4:45 p.m. CST in the Hilton Americas Houston, Ballroom of the Americas A.

  • Hillary Jacobson, DPT, a physical therapist with Roswell Park’s Transplant and Cellular Therapy Center, will discuss the importance of accurately assessing a patient’s performance status in advance of transplant and cellular therapies. Dr. Jacobson will present evidence-based tips and best practices to help guide other clinicians on how to decide which patients may benefit from rehabilitation and physical therapy, underscoring how accurate assessments can impact patient outcomes.

“The Karnofsky Performance Scale is used throughout the cancer field to help clinical professionals appropriately assess their patients’ abilities, limitations and overall health, but it’s really just the beginning,” says Dr. Jacobson. “There are still a lot of factors and variables that physical therapists and other professionals need to look at to design a program that will support optimal recovery, safety and wellness for each individual. So I will talk about how we work through some of those challenges for our patients at Roswell Park and some of the approaches that have helped us to improve our patients’ long-term outcomes and quality of life.”

Dr. Jacobson’s talk, which will be part of the Clinical Education Conference session Performance Status and Rehabilitation, will be presented Saturday, February 23, beginning at 2 p.m. CST at the Hilton Americas Houston, Ballroom of the Americas AB.

The TCT/Transplantation and Cellular Therapy Meetings (formerly the BMT Tandem Meetings) are the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and continue through Feb. 24 in Houston. Researchers from a broad range of fields and disciplines gather to share knowledge through a scientific program addressing the most timely issues in hematopoietic cell transplantation.

This release is also available on the Roswell Park website: https://www.roswellpark.org/media/news/roswell-park-presentations-tct-2019-focus-tools-predicting-patient-outcomes

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell (at) RoswellPark (dot) org.

Read the full story at https://www.prweb.com/releases/roswell_park_presentations_at_tct_meeting_focus_on_tools_for_predicting_patient_outcomes/prweb16121674.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
4. Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine
5. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
6. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
7. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
8. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
9. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
10. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
11. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):